Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

Bibliography

• PARANJAPE SM, KAMAKAKA RT, KADONAGA JT: Role ofchromatin structure in the regulation of transcription by RNA polymerase II. Ann. Rev. Biochem. (1994) 63:265–297.
   PubMed Web of Science ®Google Scholar
• LUO RX, DEAN DC: Chromatin remodeling and transcriptional regulation. J. Nail Cancer Inst. (1999) 91:1288–1292.
   PubMed Web of Science ®Google Scholar
• ••Review of role of chromatin conformation in transcriptionalcontrol.
   Google Scholar
• DAVIE JR: Covalent modifications of histones: expres-sion from chromatin templates. CUIT. Opin. Genet. Dev. (1998) 8:173–178.
   PubMed Web of Science ®Google Scholar
• HEBBES TR, THORNE AW, CRANE-ROBINSON CA: Adirect link between core histone acetylation and transcriptionally active chromatin. EMBO J. (1988) 7:1395–1402.
   PubMed Web of Science ®Google Scholar
• STRUHL K: Llistone acetylation and transcriptional regulatory mechanisms. Genes Dev. (1999) 12:599–606.
   Web of Science ®Google Scholar
• LEE KY, HAYES JJ, PRUSS D, WOLFFE AP: A positive role for histone acetylation in transcription factor access to nucleosomal DNA. Cell (1993) 72:73–84.
   PubMed Web of Science ®Google Scholar
• VETTESE-DADEY M, GRANT PA, HEBBES TR, CRANE-ROBINSON C, ALLIS CD, WORKMAN JL: Acetylation of histone H4 plays a primary role in enhancing transcription factor binding to nucleosomal DNA in vitro. EMBO J. (1996) 15:2508–2518.
   PubMed Web of Science ®Google Scholar
• YOSHIDA M, HORINOUCHI S, BEPPU T: Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. Bioassays (1995) 17:423–430.
   PubMed Web of Science ®Google Scholar
• SAMUELS BL, LARSON RA, LE BEAU MM et al.: Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. Leukemia (1988) 2:79–83.
   Google Scholar
• WANG J, SAUNTHARARAJAH Y, REDNER RL, LIU JM: Inhibitors of histone deacetylase relieve EIU-mediated repression and induce differentiation of AMU -ETO leukemia cells. Cancer Res. (1999) 59:2766–2769.
   PubMed Web of Science ®Google Scholar
• GRIGNANI F, DE MATTEIS S, NERVI C et al.: Fusionproteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukemia. Nature (1998) 391 (6669):815–818.
   PubMed Web of Science ®Google Scholar
• •Important study linking histone deacetylase mechanistically to a specific leukaemia fusion gene.
   Google Scholar
• LIN RJ, NAGY L, INOUE S, SHAO W, MILLER WH, JR., EVANS RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 391 (6669):811–814.
   PubMed Web of Science ®Google Scholar
• •Important study linking histone deacetylase mechanistically to a specific leukaemia fusion gene.
   Google Scholar
• HE L-Z, GUIDEZ F, TRIBIOLI C eta].: Distinct interactions of PML-RARalp h a and PLZF-RARalp ha with co-repressors determine differential responses to retinoic acid in acute promyelocytic leukemia. Nature Genet. (1998) 18:126–135.
   Google Scholar
• WARRELL RP, JR., HE L-Z, RICHON V, CALLEJA E, PANDOLFI PP: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst.(1998) 90 (20:1621–1625.
   PubMedGoogle Scholar
• •Case report demonstrating efficacy of addition of phenylbu-tyrate to retinoic acid for treatment of retinoid-resistant acute promyelocytic leukaemia.
   Google Scholar
• BREHM A, MISKA EA, MCCANCE DJ, REID JL, BANNISTER AJ, KOUZARIDES T: Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (1998) 391:597–601.
   PubMed Web of Science ®Google Scholar
• ALLAND L, MUHL R, HOU H et al.: Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature (1997) 387:49–55.
   PubMed Web of Science ®Google Scholar
• NAN X, NG H-H, JOHNSON CA et al.: Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature (1998) 393:386–389.
   PubMed Web of Science ®Google Scholar
• •Primary data directly linking DNA methylation with histone deacetylase in transcriptional regulation.
   Google Scholar
• CANDIDO EP, REEVES R, DAVIE JR: Sodium butyrate inhibits histone deacetylation in cultured cells. Cell (1978) 14(1):105–113.
   PubMed Web of Science ®Google Scholar
• VIDALI G, BOFFA LC, BRADBURY EM, ALLFREY VG: Butyrate suppression of histone deacetylation leads to accumulation of multiacetylated forms of histones H3 and H4 and increased DNase I sensitivity of the associ-ated DNA sequences. Proc. Natl. Acad. Sci. USA (1978) 75 (5):2239–2243.
   PubMed Web of Science ®Google Scholar
• BOFFA LC, VIDALI G, MANN RS, ALLFREY VG: Suppres-sion of histone deacetylation in vivo and in vitro by sodium butyrate./ Biol. Chem. (1978) 253(10):3364–3366.
   Google Scholar
• KRUH J: Effects of sodium butyrate, anew pharmacol-ogical agent, on cells in culture. Mol. Cell Biochem. (1982) 42(2):65–82.
   PubMed Web of Science ®Google Scholar
• OHLSSON-WILHELM BM, FARLEY BA, KOSCIOLEK B, LABELLA S, ROWLEY PT: K562 human erythroleukemia cell variants resistant to growth inhibition by butyrate have deficient histone acetylation. Am. J. Hum. Genet. (1984) 36(6):1225–1238.
   PubMed Web of Science ®Google Scholar
• LEA MA, RANDOLPH VM, HODGE SK: Induction of histone acetylation and growth regulation in eryrthro-leukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res. (1999) 1 9 (3A) :1971–1976.
   Google Scholar
• •Comparison of pharmacodynamic effects of phenylbutyrate and analogues.
   Google Scholar
• YU KH, WENG L-J, FU S, GORE SD: Augmentation of phenylbutyrate-induced differentiation of myeloid leukemia cells using all trans-retinoic acid. Leukemia (1999) 13:1258–1265.
   PubMed Web of Science ®Google Scholar
• •Investigation of pharmacodynamic synergy between phenylbutyrate and retinoids.
   Google Scholar
• LEA MA, TULSYAN N: Discordant effects of butyrate analogues on erythroleukemia cell proliferation, differentiation and histone deacetylase. AnticancerRes. (1995) 15 (3):879–883.
   PubMed Web of Science ®Google Scholar
• SAMID D, SHACKS, SHERMAN LT: Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res. (1992) 52:1988–1992.
   PubMed Web of Science ®Google Scholar
• SAMID D, SHACK S, MYERS CE: Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. j an. Invest. (1993) 91:2288–2295.
   PubMed Web of Science ®Google Scholar
• SAMID D, RAM Z, HUDGINS WR et al.: Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylke-tonuria. Cancer Res. (1994) 54 :891–895.
   PubMed Web of Science ®Google Scholar
• LIU L, SHACK S, STETLER-STEVENSON M, HUDGINS WR,SAMID D: Differentiation of cultured human melanoma cells induced by the aromatic fatty acids phenylacetate and phenylbutyrate. J. Investig. Dermatol. (1994) 103:335–340.
   PubMed Web of Science ®Google Scholar
• DIGIUSEPPE JA, WENG L-J, YU KH et al.:Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-Function Analysis. Leukemia (1999) 13:1243–1253.
   PubMed Web of Science ®Google Scholar
• •Comparison of pharmacodynamic effects of phenylbutyrate, butyric acid and phenylacetate in a myeloid leukaemia cell line.
   Google Scholar
• GORE SD, SAMID D, WENG L-J: Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentia-tion and apoptosis of primary neoplastic myeloid cells. Clin. Cancer Res. (1997) 3:1755–1762.
   PubMed Web of Science ®Google Scholar
• PELIDIS MA, CARDUCCI MA, SIMONS JW: Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines. Int. J. Oncol. (1998) 12 (4):889–893.
   PubMed Web of Science ®Google Scholar
• CARDUCCI MA, NELSON JB, CHAN-TACK KM et al: Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin. Cancer Res. (1996) 2:379–387.
   PubMed Web of Science ®Google Scholar
• PINEAU T, HUDGINS WR, LIU C et al.: Activation of a peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs. Biochem. Pharmacol. (1996) 52:659–667.
   PubMed Web of Science ®Google Scholar
• BRUSILOW SW, FINKELSTIEN J: Restoration of nitrogen homeostasis in a man with ornithine transcarbamy-lase deficiency. Metabolism (1993) 42:1336–1339.
   PubMed Web of Science ®Google Scholar
• BRUSILOW SW, DANNEY M, WABER LJ et al: Treatmentof episodic hyperammonemia in children with inborn errors of metabolism. N. Engl. J. Med. (1984) 310:1630–1634.
   PubMed Web of Science ®Google Scholar
• BRUSILOW SW: Treatment of urea cycle disorders.(1994)79–94.
   Google Scholar
• MAESTRI NE, HAUSER ER, BARTHOLOMEW D, BRUSILOWSW: Prospective treatment of urea cycle disorders. J Pediatrics (1991) 119:923–928.
   PubMed Web of Science ®Google Scholar
• MITCHELL RB, WAGNER JE, KARP JE et al.: Syndrome ofidiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am. J. Med. (1988) 85:662–667.
   PubMed Web of Science ®Google Scholar
• COLLINS AF, PEARSON HA, GIARDINA P, MCDONAGH KT, BRUSILOW SW, DOVER GJ: Oral sodium phenylbu-tyrate therapy in homozygous beta thalassemia: a clinical trial. Blood (1995) 85 (0:43–49.
   PubMedGoogle Scholar
• DOVER G, BRUSILOW S, SAMID D: Increased fetalhemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl. J. Med. (1992) 327:569–570.
   PubMed Web of Science ®Google Scholar
• DOVER GJ, BRUSILOW S, CHARACHE S: Induction offetal hemoglobin production in subjects with sickle cell anaemia by oral sodium phenylbutyrate. Blood (1994) 84:339–343.
   PubMed Web of Science ®Google Scholar
• BRUSILOW SW: Phenylacetylglutamine may replaceurea as a vehicle for waste nitrogen excretion. Pediatric Res. (1991) 29:147–150.
   PubMed Web of Science ®Google Scholar
• ISHIGURO K, SARTORELLI AC: Coinduction ofembryonic and adult-type globin mRNAs by sodium butyrate and trichostatin Ain two murine interleukin-3-dependent bone marrow-derived cell lines. Blood (1998) 92(10:4383–4393.
   PubMedGoogle Scholar
• PERRINE SP, FALLER DV, SWERDLOW P et al: Stoppingthe biologic clock for globin gene switching. Ann. NY Acad. Sci. (1990) 612:134–140.
   PubMed Web of Science ®Google Scholar
• NOVOGRODSKY A, DVIR A, RAVID A et al.: Effect ofpolar organic compounds on leukemic cells. Butyrate-induced partial remission of acute myelogenous leukemia in a child. Cancer (1983) 51:9–14.
   Google Scholar
• MILLER AA, KURSCHEL E, OSIEKA R, SCHMIDT CG: Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur. J. Cancer. .Clin. Oncol. (1987) 23:1283–1287.
   PubMedGoogle Scholar
• CONLEY BA, EGORIN MJ, TAIT N et al: Phase I study ofthe orally administered butyrate prodrug, tributyrin, in patients with solid tumors. an. Cancer Res. (1998) 4 (3):629–634.
   Web of Science ®Google Scholar
• THIBAULT A, COOPER MR, FIGG WD et al.: APhase land pharmacokinetic study of intravenous phenylacetate in patients with cancer. Cancer Res. (1994) 54:1690–1694.
   PubMed Web of Science ®Google Scholar
• ••Phase I study of phenylacetate in patients with malignancy.
   Google Scholar
• THIBAULT A, SAMID D, COOPER MR et al: Phase I study of phenylacetate administered twice daily to patients with cancer. Cancer (1995) 7 5 (12):2932–2938.
   Google Scholar
• ••Phase I study of twice daily phenylacetate in malignancy.
   Google Scholar
• CHANG SM, KUHN JG, ROBINS HI et al: Phase II study of phenylacetate in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J. Clin. Oncol (1999) 17(3):984–990.
   PubMed Web of Science ®Google Scholar
• BUCKNER JC, MALKIN MG, REED E etal.: Phase II study of antineoplastons A10 (NSC 648539) and A52-1 (NSC 620261) in patients with recurrent glioma. Mayo Clin. Proc. (1999) 74(2):137–145.
   Google Scholar
• PISCITELLI SC, THIBAULT A, FIGG WD et al.: Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J. Clin. Pharmacol. (1995) 35 (4):368–373.
   PubMed Web of Science ®Google Scholar
• ••Pharmacokinetic analysis of phenylbutyrate; no clinicaldata.
   Google Scholar
• CARDUCCI MA, BOWLING MK, EISENBERGER MA et al.: Phenylbutyrate for refractory solid tumors: a Phase I clinical and pharmacologic evaluation. Proc. Amer. Soc. Oncol. (1996) 15:485.
   Google Scholar
• •Abstract describing Phase I study of phenylbutyrate in solid tumours.
   Google Scholar
• GORE SD, MILLER CB, WENG L-J et al.: Improved hematopoiesis in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) following administration of the putative differenti-ating agent sodium phenylbutyrate (SPB). Blood (1996) 88 (Suppl. 1):582a.
   Google Scholar
• •Abstract describing Phase I study of phenylbutyrate in haematologic malignancies.
   Google Scholar
• GORE SD, MILLER CB, WENG L-J et al: Clinical develop- ment of sodium phenylbutyrate (SPB) as a putative differentiating agent in myeloid malignancies. AntiCancer Res. (1997) 17:3938.
   Google Scholar
• BOWLING MK, NELSON JB, TONG KP et al.: Biomarker responses in men with advanced prostate cancer (PCA) to infusional phenylbutyrate (PB). Proc Am. Soc. Clin. Oncol. (1996) 15:A43–
   Google Scholar
• GORE SD, WENG L-J, GRIFFIN CA et al.: Impact of prolonged administration of the putative differenti-ating agent sodium phenylbutyrate (PB) on hematopoeisis in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Blood (1998) 92 (Suppl. 1) :633a.
   Google Scholar
• ••Abstract describing feasibility of prolonged out-patientadministration of continuous infusion phenylbutyrate.
   Google Scholar
• CARDUCCI MA, BOWLING M, EISENBERGER M et al.: Oral sodium phenylbutyrate for refractory solid tumors: Phase land bio availability assessment. Proc. Amer. Soc. Clin. Oncol. (2000) 17:215a.
   Google Scholar
• •Abstract describing Phase I trial of oral phenylbutyrate.
   Google Scholar
• FISHER JD, CARDUCCI MA, BAKER SD et al. AND THENABTT CNS CONSORTIUM: Dose escalation study of oral sodium phenylbutyrate (PB) in patients with refractory high grade astrocytomas: maximum tolerated dose, toxicity profile, pharmacology and survival. Proc. Am. Soc. Clin. Oncol. (2000) 19:166a.
   Google Scholar
• BREITMAN TR, HER: Combinations of retinoic acid witheither sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HILO. Cancer Res. (1990) 60:6268–6273.
   Google Scholar
• MINUCCI S, HORN V, BHATTACHARYYA N et al.: A histone deacetylase inhibitor potentiates retinoid receptor action in embryonal carcinoma cells. Proc. Natl. Acad. ScL USA (1997) 94(20:11295–11300.
   PubMedGoogle Scholar
• YU KH, WENG L-J, FU S, GORE SD: Augmentation ofphenylbutyrate-induced differentiation of myeloid leukemia cells using all trans-retinoic acid. Leukemia (2000) 13:1258–1265.
   Web of Science ®Google Scholar
• PILI R, KRUSZEWSKI M, HAGER B, PIETTE C, CARDUCCI MA: Inhibition of tumor growth and angiogenesis by combination of phenylbutyrate and 13-cis retinoic acid in human and rodent tumors. Proc. Am. Assoc. Cancer Res. (2000) 41:14.
   Google Scholar
• CAMERON EE, BACHMAN KE, MYOHANEN S, HERMAN JG, BAYLIN SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. (1999) 21:103–107.
   PubMed Web of Science ®Google Scholar
• ••Primary data demonstrating synergy between DNA methyl-transferase inhibition and histone deacetylase inhibition for re-expression of transcriptionally silenced genes.
   Google Scholar
• WITZIG TE, TIMM M, STENSON M, SVINGEN PA, KAUFMANN SH: Induction of ap o p to sis in malignant B cells by phenylbutyrate or phenylacetate in combina-tion with chemotherapeutic agents. an. Cancer Res. (2000) 6(2):681–692.
   Web of Science ®Google Scholar
• •Manuscript detailing synergy of apoptosis induction between phenylbutyrate and cytotoxic agents.
   Google Scholar
• HUANG Y, WAXMAN S: Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin. Cancer Res. (1998) 4(10)2503–2509.
   Google Scholar
• HUANG Y, HORVATH CM, WAXMAN S: Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin and phenylbutyrate. Cancer Res. (2000) 60 (12):3200–3206.
   PubMed Web of Science ®Google Scholar
• SUNG MW, WAXMAN S: Chemodifferentiation therapy with fluorouracil and phenylbutyrate in advanced colorectal cancer: A Phase I trial. Proc. Am. Assoc. Cancer Res. (1999) 40:339.
   Google Scholar
• NAKAJIMA H, KIM YB, TERANO H, YOSHIDA M: FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. (1998) 241:126–133.
   PubMed Web of Science ®Google Scholar
• RAJGOLIKAR G, CHAN KK, WANG HC: Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells. Breast Cancer Res. Treat. (1998) 51 (1):29–38.
   PubMed Web of Science ®Google Scholar
• BYRD JC, SHINN C, RAVI R et al.: Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lympho-cytic leukemia cells [published erratum appears in Blood 2000 Jan 15;95(2):409]. Blood (1999) 94(01401–1408.
   PubMed Web of Science ®Google Scholar
• RICHON VM, EMILIANI S, VERDIN E et al.: A class of hybrid polar inducers of transformed cell differentia-tion inhibits histone deacetylases. Proc. Natl. Acad. ScL USA (1998) 95 (6) :3003–3007.
   PubMed Web of Science ®Google Scholar
• BUTLER LM, AGUS DB, SCHER HI et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res. (2000) 60 (18) :5165–5170.
   PubMed Web of Science ®Google Scholar
• COHEN LA, AMIN S, MARKS PA, RIFKIND RA, DESAI D, RICHON VM: Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (2000) 9(12) cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res. (1999) 19 (613):4999–5005.
   Google Scholar
• MARKS PA, RICHON VM, RIFKIND RA: Ilistone deacety-lase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J. Nail Cancer Inst. (2000) 92(15):1210–1216.
   PubMed Web of Science ®Google Scholar
• SAITO A, YAMASHITA T, MARIKO Y et al.: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA (4-13-1999) 96 (8):4592–4597.
   Google Scholar
• DOLBEARE F, KUO W-L, BEISKER W, VANDERLAAN M, GRAY JW: Using monoclonal antibodies in bromodeoxyuridine-DNA analysis. Methods Cell Biol. (1990) 33:227–234.
   PubMedGoogle Scholar
• KOOPMAN G, REUTELINGSPERGER CP, KUIJTEN G. et al.: Annexin Vfor flow cytometric detection of phosphati-dylserine expression on B cells undergoing apoptosis. Blood (1994) 84 (5) :1415–1420.
   Google Scholar